Gabriel S Harris, Abigail C Alexander, Titania N Bethiana, Shrinidhi Ravi, Kofi B Owusu, Herman O Sintim, Kurt D Ristroph, Marxa L Figueiredo
{"title":"STING-inhibitor-phenamil polymeric nanocarriers for the in vitro modulation of macrophage polarization.","authors":"Gabriel S Harris, Abigail C Alexander, Titania N Bethiana, Shrinidhi Ravi, Kofi B Owusu, Herman O Sintim, Kurt D Ristroph, Marxa L Figueiredo","doi":"10.1016/j.biopha.2026.120036","DOIUrl":"https://doi.org/10.1016/j.biopha.2026.120036","url":null,"abstract":"<p><p>Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic inflammation and polyarthritis. RA has no cure and imposes a significant burden on individuals because current standard-of-care anti-inflammatory treatments reduce inflammation by regulating lymphocyte proliferation and pro-inflammatory cytokine function. However, recent studies have shown that macrophages play a pivotal role in the progression of RA and therefore, we hypothesize that co-loaded nanocarriers (NCs) containing a STING inhibitor and phenamil can reduce inflammation by repolarizing macrophages from a pro-inflammatory (M1-like) to an anti-inflammatory (M2-like) phenotype. Using Flash NanoPrecipitation (FNP), both compounds were encapsulated into polymeric nanocarriers which were then tested for their ability to induce an anti-inflammatory phenotype in vitro. Macrophage NF-κB activation levels were assessed using a reporter cell line, gene expression via qRT-PCR, and polarization state via flow cytometry. NF-κB activity was monitored using a cell line that secretes embryonic alkaline phosphatase upon activation; reductions in this signal indicate suppression of inflammatory signaling. Key markers examined for an anti-inflammatory phenotype for macrophages included IL-1β, IL-6, IL-10, and TGF-β. Finally, by assessing the ratio of M2-like to M1-like macrophages, we sought to determine if these formulations could successfully repolarize macrophages from M1-like to M2-like, and/or help macrophages resist polarization to an M1-like state following exposure to a pro-inflammatory stimulus. Through this work, we aimed to investigate how nanotechnology can be leveraged to improve therapeutic outcomes by regulating macrophage polarization states.</p>","PeriodicalId":93904,"journal":{"name":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","volume":"205 ","pages":"120036"},"PeriodicalIF":7.5,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149396558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Fourth-generation multi-costimulatory chimeric antigen receptor T cells targeting CD133 and integrin αvβ6 exert potent antitumor activity in cholangiocarcinoma.","authors":"Tullayakorn Plengsuriyakarn, Thanich Sangsuwannukul, Kamonlapat Supimon, Chalermchai Somboonpatarakun, Mutita Junking, Pa-Thai Yenchitsomanus, Kesara Na-Bangchang","doi":"10.1016/j.biopha.2026.120045","DOIUrl":"https://doi.org/10.1016/j.biopha.2026.120045","url":null,"abstract":"<p><p>Cholangiocarcinoma (CCA) is an aggressive and highly metastatic malignancy with limited responsiveness to conventional chemotherapy, underscoring the need for innovative therapeutic strategies. This study aimed to develop and evaluate fourth-generation chimeric antigen receptor (CAR) T cells (CAR4; a multi-costimulatory CD28/4-1BB/CD27/CD3ζ design without a cytokine or other transgene payload) targeting CD133 and integrin αvβ6 to treat CCA. Two parallel CAR T-cell products, each incorporating a single antigen-recognition domain, were generated and evaluated independently rather than as one bispecific construct. We transduced activated human T lymphocytes with lentiviral constructs encoding anti-CD133 CAR4 and an integrin-targeted CAR (A20 CAR4), confirmed CAR expression by flow cytometry, then expanded them in vitro and evaluated therapeutic efficacy after intratumoral administration in a CCA xenograft nude mouse model. CAR4 T-cell treatment produced dose-dependent suppression of tumor growth and significant prolongation of survival compared with control and untreated groups. High-dose anti-CD133 and anti-integrin CAR4 T cells achieved greater tumor inhibition and numerically extended median survival beyond that observed with cisplatin. Histopathological analysis revealed no treatment-related abnormalities in heart, liver, spleen, or kidney tissues, and lung metastasis incidence was markedly reduced in high-dose CAR-treated groups. Quantitative real-time PCR analysis demonstrated coordinated downregulation of genes associated with angiogenesis (VEGF), matrix remodeling (MMP9), inflammatory signaling (COX-2, mPGES-1, TNF-α, IL-6), and immunosuppressive pathways (TGF-β, IL-10). These findings indicate that fourth-generation CAR T cells targeting CD133 and integrin αvβ6 exert potent antitumor activity in this model and that their activity is associated with transcript-level downregulation of tumor microenvironment-related genes, suggesting potential modulation of the tumor microenvironment that will require protein-level and functional confirmation. Antigen-dependent cytotoxicity was not directly assessed in vitro in the present study. Together, these data support further translational development of multi-costimulatory CAR T-cell platforms for CCA.</p>","PeriodicalId":93904,"journal":{"name":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","volume":"205 ","pages":"120045"},"PeriodicalIF":7.5,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149389008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aphiwe P Gumede, Darian Naidu, Kensane Mthembu, Murunwa Maimela, Omolara O Baiyegunhi, Nompumelelo P Mkhwanazi
{"title":"Early-stage inhibition of HIV-1 subtypes A, B, and C gag- protease chimeras by Penicillium chrysogenum P03MB2 metabolites and activity against cell-to-cell spread.","authors":"Aphiwe P Gumede, Darian Naidu, Kensane Mthembu, Murunwa Maimela, Omolara O Baiyegunhi, Nompumelelo P Mkhwanazi","doi":"10.1016/j.biopha.2026.120033","DOIUrl":"https://doi.org/10.1016/j.biopha.2026.120033","url":null,"abstract":"<p><p>Despite the success of antiretroviral therapy, human immunodeficiency virus type 1 (HIV-1) cell-to-cell spread remains a major barrier to viral eradication. This study evaluated the antiviral activity of secondary metabolite fractions derived from Penicillium chrysogenum P03MB2 against cell-free HIV-1 infection of patient-derived Gag-protease chimeric viruses representing HIV-1 subtypes A, B, and C, and investigated its impact on cell-to-cell spread. Crude fungal extracts from oat-grown cultures were fractionated using mixed-mode cation exchange (MCX) solid-phase extraction. Cytotoxicity was assessed in TZM-bl cells by MTT assay, antiviral activity was evaluated using a luciferase reporter assay. In silico molecular docking explored predicted interactions between five identified metabolites, including Cytochalasin J, and entry-associated targets (CCR5, CXCR4, and gp120). Cell- to cell transmission was assessed using Jurkat co-culture assays and flow cytometry. The 45% MCX Oats fraction emerged as the most active candidate exhibiting low cytotoxicity (CC₅₀ > 300 µg/mL) and potent antiviral activity across all chimeric variants (IC₅₀: 0.221-1.007 µg/mL; Selectivity Indices: 271-1235). Time-of-addition analysis indicated that maximal inhibition during the early infection stages. Molecular docking identified favourable predicted binding compatibility for Cytochalasin J against CCR5 (reaching -10.9 kcal/mol), CXCR4, and gp120 targets, sharing predicted interacting residues with reference drugs. Furthermore, the fraction significantly reduces newly infected target cells in the cell-to-cell transmission model compared to untreated controls. Collectively, these findings demonstrate that 45% MCX Oats fraction exhibits potent antiviral activity against cross-clade antiviral activity against HIV-1 Gag-Pro chimeras and limits viral transmission in vitro, supporting further bioassay-guided isolation of its active constituents.</p>","PeriodicalId":93904,"journal":{"name":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","volume":"205 ","pages":"120033"},"PeriodicalIF":7.5,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149389007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Atlanta Borah, Jashaswi Priyadarshini Jena, Macha Vijay, Annie Okram, Gowtham M, Niveditha P, Sukhadeo B Barbuddhe, Nagendra R Hegde, Deepak B Rawool, Anand Srivastava
{"title":"Formononetin disrupts MRSA biofilm via potential SarA-associated regulatory modulation.","authors":"Atlanta Borah, Jashaswi Priyadarshini Jena, Macha Vijay, Annie Okram, Gowtham M, Niveditha P, Sukhadeo B Barbuddhe, Nagendra R Hegde, Deepak B Rawool, Anand Srivastava","doi":"10.1016/j.biopha.2026.120028","DOIUrl":"https://doi.org/10.1016/j.biopha.2026.120028","url":null,"abstract":"<p><p>Biofilm formation is a crucial aspect of Methicillin-resistant Staphylococcus aureus (MRSA) pathogenesis and contributes to its resistance against conventional antibiotics. This study reports the identification of a bioactive molecule, formononetin, from Glycyrrhiza glabra L., that is effective against MRSA. Formononetin significantly inhibited biofilm formation, disrupted sessile biofilm, and reduced the hemolytic activity of MRSA in a dose-dependent manner. Formononetin also increased the survival rate of MRSA-infected G. mellonella larvae by decreasing the bacterial load and increasing melanization. The combination of formononetin with antibiotics, like oxacillin, ampicillin, and streptomycin, showed a fractional inhibitory concentration index (FICI) ≤ 0.5, which indicates a synergistic effect. Molecular docking studies showed formononetin can bind to the global regulator, SarA, with an estimated binding score of -6.176 kcal/mol. Further, the aspartate residue (D20) in SarA was identified as a binding site for formononetin. Microscale thermophoresis and electrophoretic mobility shift assay of the SarAD20A mutant showed reduced affinity towards formononetin without affecting its DNA-binding activity compared to its wild-type counterpart. Further, proteomic profiling of MRSA upon treatment with formononetin showed significant modulation of SarA and SarA-related pathways, such as scdA and agrC. Our findings suggest that formononetin holds promise as a natural agent for combating MRSA biofilm.</p>","PeriodicalId":93904,"journal":{"name":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","volume":"205 ","pages":"120028"},"PeriodicalIF":7.5,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149382277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Corrigendum to \"Revolution in biomedicine using emerging of picomaterials: A breakthrough on the future of medical diagnosis and therapy\" [BIOPHA, 120 (2019), 109484].","authors":"Paria Pashazadeh-Panahi, Mohammad Hasanzadeh","doi":"10.1016/j.biopha.2026.120032","DOIUrl":"https://doi.org/10.1016/j.biopha.2026.120032","url":null,"abstract":"","PeriodicalId":93904,"journal":{"name":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","volume":" ","pages":"120032"},"PeriodicalIF":7.5,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149358444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}